|Awarded On||August 18, 2021|
|Title||Improving CAR T-cell therapy of T-ALL by co-targeting additional antigens|
|Award Mechanism||High Impact/High Risk|
|Institution/Organization||Baylor College of Medicine|
|Principal Investigator/Program Director||Maksim Mamonkin|
|Cancer Sites||Leukemia, Lymphoma|
*Pending contract negotiation
Patients with B-cell leukemia can benefit tremendously from the latest generation of targeted cellular immunotherapies where their own killer cells (called T-cells) are engineered with special molecules called chimeric antigen receptors (CARs) which recognize and kill tumor cells. In stark contrast, patients with T-cell leukemia (T-ALL) lack any options for those life-saving treatments and mostly have to rely on conventional chemotherapies, which can be toxic and not always effective. Developing CAR T-cell therapies for patients with T-ALL is very challenging because the protein targets that the CARs can recognize are often present on vital tissues, including T-cells themselves. This can lea...